Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
ID: 348234Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/348234

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-193.html
Timeline
    Description

    The National Institutes of Health (NIH), through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has announced a funding opportunity titled "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)." This initiative aims to facilitate the development of non-hormonal contraceptives and reproductive health products by providing access to essential preclinical services, including protein generation, high throughput screening, and drug metabolism studies, rather than direct funding. The program is particularly significant in addressing the urgent need for effective contraceptive methods and advancing innovative research in reproductive health. Interested applicants, including various educational and community organizations, must adhere to specific guidelines and submit their applications by April 3, 2026, with an initial deadline of October 3, 2023. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-193.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-193-Full-Announcement.html
    PAR-23-193.html
    The Department of Health and Human Services, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), has released a funding opportunity aimed at facilitating the development of non-hormonal contraceptives and reproductive health products via its Chemical Screening and Optimization Facility (CSOF). This initiative, designated as the X01 Resource Access Award, does not provide direct funding but offers access to various preclinical services essential for research, including protein generation, high throughput screening, and drug metabolism studies. Key details include application deadlines of October 3, 2023, and repeated cycles until 2026. The goal is to enable the advancement of projects that show promise in reproductive health, thereby addressing the urgent need for effective contraceptive methods. Applicants are encouraged to reach out to NICHD staff for guidance prior to submission. The application process requires adherence to specific guidelines, with an emphasis on target validation and the expected impacts on product development. Researchers must demonstrate compliance with NIH policy and clear project advancement plans. Overall, this funding opportunity aims to push forward innovative research while ensuring strong support for public health initiatives related to reproductive health.
    Similar Opportunities
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at advancing contraceptive development programs through the provision of specialized services. This funding opportunity announcement (FOA) is designed to support innovative and validated methods that are essential for future clinical development, allowing applicants who may not currently hold NIH funding to apply, although priority may be given to those with existing NIH support. The grant is categorized under Income Security and Social Services, with no cost-sharing or matching requirements, and is open to a diverse range of eligible applicants, including various educational institutions and organizations. Interested parties should note that the application deadline is May 2, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-128.html.
    Biological Testing Facility (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Biological Testing Facility (X01 Clinical Trial Not Allowed)" aimed at supporting research in the development of non-hormonal contraceptive methods. This grant allows investigators to access the Biological Testing Facility (BTF) for preclinical studies and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies, with a focus on advancing contraceptive development to address unintended pregnancies in the U.S. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofits, and foreign entities, with applications due by May 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-192.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    NICHD Small Research Grant Program (R03 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03 Clinical Trial Required) to support clinical trials that align with the mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This grant program is designed to fund small research projects with a maximum budget of $50,000 in direct costs per year, for a duration of up to two years, focusing on areas such as human development, childhood development, and rehabilitation medicine. Eligible applicants include a diverse range of organizations, including higher education institutions, nonprofits, for-profits, and tribal governments, with all applications required to propose clinical trials and adhere to NIH submission guidelines. Interested parties should note that the application deadline is January 7, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further inquiries. More information can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-21-221.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NICHD Small Research Grant Program (R03), which supports small clinical trials focused on basic experimental studies involving human participants. This funding opportunity aims to enhance understanding of fundamental phenomena without immediate application towards products or processes, aligning with the NICHD's mission in human development, behavior, and health. Grants are available for up to $50,000 in direct costs per year, with a maximum project duration of two years, and applications must be submitted by January 7, 2025. Interested applicants can find more information and application details at the NIH website or contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance.
    Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)" aimed at supporting the development of innovative Multipurpose Prevention Technologies (MPTs) that prevent HIV, sexually transmitted infections (STIs), and pregnancy. The initiative encourages applications that focus on both event-driven and long-acting MPTs, integrating user-desired features to enhance adoption and adherence, while also promoting biobehavioral research alongside pharmacokinetic and pharmacodynamic studies. This funding opportunity is open to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations, with applications due by December 7, 2024. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-180.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy" under the R01 grant mechanism, which does not allow clinical trials. This initiative aims to support the development and clinical validation of innovative, non-invasive methods to assess placental health throughout pregnancy, addressing critical issues such as preeclampsia and stillbirth. The funding is part of the Human Placenta Project and encourages applications from a diverse range of organizations, including educational institutions and community-based organizations, with no budget limits specified, although proposals should reflect actual project needs. Interested applicants must submit their proposals by November 5, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.